Legacy Healthcare Launches Phase 3 Trial for Alopecia Areata Treatment Cinainu Following FDA Approval Legacy Healthcare is set to advance Cinainu, a topical solution for alopecia areata, into an international Phase 3 trial after receiving FDA clearance.

Legacy Healthcare Launches Phase 3 Trial for Alopecia Areata Treatment Cinainu Following FDA Approval #United_States #Alopecia_Areata #Epalinges #Cinainu #Legacy_Healthcare

Pilatus Biosciences Unveils Groundbreaking Data on PLT012 at SITC 2025 Annual Meeting At SITC 2025, Pilatus Biosciences reveals impressive findings on its lead candidate PLT012, showcasing its dual mechanism to combat solid tumors.

Pilatus Biosciences Unveils Groundbreaking Data on PLT012 at SITC 2025 Annual Meeting #Switzerland #Pilatus_Biosciences #PLT012 #Epalinges #SITC_2025

Onward Therapeutics Partners with Institut du Cancer for Major Onco-Metabolism Licensing Deal Onward Therapeutics has signed a worldwide license agreement with Institut du Cancer de Montpellier to advance their innovative Onco-Metabolism program, aimed at enhancing cancer treatment.

Onward Therapeutics Partners with Institut du Cancer for Major Onco-Metabolism Licensing Deal #Switzerland #Onward_Therapeutics #Epalinges #Institut_du_Cancer #Onco-Metabolism

Onward Therapeutics Receives EMA Approval to Begin Clinical Trials for Novel NK Cell Therapy in Cancer Treatment Onward Therapeutics has gained EMA approval for its subsidiary Emercell to conduct clinical trials for its innovative NK cell therapy, OT-C001, targeting cancer.

Onward Therapeutics Receives EMA Approval to Begin Clinical Trials for Novel NK Cell Therapy in Cancer Treatment #Switzerland #Onward_Therapeutics #Emercell #OT-C001 #Epalinges